B+
Bull case
25%
Probability
Target price
$7.00
+77.2% vs current
ZNTL
ZentalisANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$4.30
+8.9% vs current
B-
Bear case
25%
Probability
Target price
$2.00
-49.4% vs current
AI sentiment snapshot
Latest data as of 2026-05-28
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+60.4
Score
AI commentary
Primary-source coverage is solid but still filing-based, and the packet contains no recent trusted-news or social follow-through. The late-2027 runway reduces immediate financing pressure, but the setup remains a low-coverage, binary-event small-cap biotech with valuation keyed to DENALI and limited analyst validation, so this remains a tentative monitoring view rather than a high-conviction directional call.
RankAlpha Sentiment Codex - 2026-05-28
Open full AI memoEvidence flagged
Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.
Impact
tentative
Confidence
-
AI events
2026-05-12eventASPENOVA Phase 3 dosing started, confirming the next clinical execution stepMedium impact
The Q1 2026 filing's subsequent-events disclosure states that the first patient was dosed in the Phase 3 ASPENOVA trial and that a $7.0 million milestone payment was incurred, confirming the confirmatory program is underway while adding a near-term cash use item [#10-Q-2026-05-12].
2026-05-12catalystQ1 2026 filing confirms runway but burn remains the near-term watch itemMedium impact
The latest 10-Q indicates cash, cash equivalents and marketable securities of $211.8 million as of March 31, 2026 and suggests funding into late 2027, which lowers immediate financing pressure but does not remove the need to monitor ongoing operating losses and spending discipline [#10-Q-2026-05-12].
2026-12-31catalystDENALI Part 2 topline remains the main binary value driver for 2026High impact
The 2025 10-K frames the DENALI program as the key longer-dated catalyst; if Part 2 data are positive, the company could pursue an accelerated-approval path subject to FDA review, making year-end 2026 topline the principal valuation inflection point [#10-K-2026-03-26].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-28 • Updated nightlySource: Internal modelMethodology